Press Releases

To see only press releases which have been disclosed pursuant to legislation or other regulations, please select “Regulatory releases” below.


Business highlights in Q1 2023 In March the Company announced the completion of dosing of all 24 patients the the Phase IIa clinical trial with IP2018 and that preliminary results are expected end…

Initiator Pharma has decided not to exercise the option for an undisclosed pain asset

Initiator Pharma A/S, a clinical-stage pharma company, announced today its decision not to exercise the exclusive option agreement for a Phase II/III ready pharmaceutical asset. With this decision the company reiterates previous statement that its current cash position will be sufficient to fund all planned and committed activities through 2024.